What prenatal labs are recommended for pregnant individuals?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Prenatal Laboratory Tests for Pregnant Individuals

All pregnant individuals should undergo comprehensive prenatal laboratory screening to identify potential health risks and prevent complications affecting maternal and fetal outcomes.

First Prenatal Visit (Ideally Before 12 Weeks)

Blood Tests

  • Complete blood count (CBC) to assess for anemia and platelet abnormalities 1
  • Blood type and Rh status with antibody screen (high strength of evidence) 2
    • Rh-negative women require Rh immune globulin at 28 weeks gestation 2
  • Infectious disease screening:
    • HIV testing for all pregnant women (universal recommendation) 3
    • Hepatitis B surface antigen (HBsAg) 3, 2
    • Syphilis serology 3, 4
    • Rubella antibody status to determine immunity 1
    • Varicella immunity testing if history unclear 1
  • Genetic carrier screening based on family history, ethnicity, and risk factors 2

Urine Tests

  • Urinalysis and urine culture for asymptomatic bacteriuria 5
  • Chlamydia and gonorrhea screening (especially for high-risk populations) 3, 4

Supplementation

  • Folic acid supplementation (400-800 mcg daily) to prevent neural tube defects 6, 5
    • Higher doses may be needed for women with specific risk factors

Second Trimester (15-20 Weeks)

Genetic Screening

  • Maternal serum AFP screening for neural tube defects, optimally between 16-18 weeks 3
  • Multiple marker screening (quad screen) including:
    • Alpha-fetoprotein (AFP)
    • Human chorionic gonadotropin (hCG)
    • Unconjugated estriol (uE3)
    • Inhibin-A (INH-A) 3, 2

Anatomic Assessment

  • Detailed ultrasound for fetal anatomy assessment at 18-22 weeks 2

24-28 Weeks

Metabolic Screening

  • Gestational diabetes screening using 50g oral glucose challenge test 2, 5
    • Follow-up with 3-hour glucose tolerance test if initial screen is abnormal

Hematologic Assessment

  • Repeat CBC to assess for pregnancy-related anemia
  • Administration of Rh immune globulin for Rh-negative women 2

35-37 Weeks

Infectious Disease Screening

  • Group B Streptococcus (GBS) vaginal-rectal culture 3, 4
    • Positive results require intrapartum antibiotic prophylaxis to prevent neonatal infection

Special Considerations

High-Risk Pregnancies

  • Hepatitis C antibody testing for women with history of injection drug use or transfusion/organ transplant before 1992 3
  • Tuberculosis screening for women who use drugs illicitly 3
  • Aspirin 81mg daily starting at 12 weeks for women at risk of preeclampsia 5

Imaging Considerations

  • Ultrasound without contrast is the preferred imaging modality throughout pregnancy 3
  • MRI without gadolinium is preferred over CT when advanced imaging is needed 3
  • Abdominal CT without contrast is generally safe but cumulative radiation exposure should be kept below 50 mGy 3

Implementation Considerations

Documentation Requirements

  • The Joint Commission requires documentation of maternal disease status for HIV, hepatitis B, syphilis, and GBS in both maternal and newborn medical records 4
  • Immediate peripartum testing is required for women with inadequate prenatal screening 4

Testing Refusal

  • While universal testing is recommended, testing should remain voluntary 3
  • Women who refuse testing should not be coerced, denied care, or threatened with negative consequences 3
  • Providers should address reasons for refusal through education and trust-building 3

Pitfalls to Avoid

  • Delayed initiation of prenatal care - care initiated at 10 weeks or earlier improves outcomes 5
  • Risk-based testing approaches identify fewer HIV-infected women than universal screening 3
  • Failure to retest women who initially refuse testing or who are at ongoing risk 3
  • Inadequate follow-up of positive screening results 4
  • Incorrect gestational age dating affecting interpretation of screening results 2

Proper implementation of these prenatal laboratory tests significantly reduces maternal and fetal morbidity and mortality by enabling early detection and management of conditions that could adversely affect pregnancy outcomes.

References

Guideline

Prenatal Screening and Diagnostic Testing

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Prenatal Care: An Evidence-Based Approach.

American family physician, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.